195 related articles for article (PubMed ID: 7086136)
41. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
Bhardwaj S; Vasishta RK; Arora SK
Exp Parasitol; 2009 Jan; 121(1):29-37. PubMed ID: 18983842
[TBL] [Abstract][Full Text] [Related]
42. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.
Satoskar AR; Rodig S; Telford SR; Satoskar AA; Ghosh SK; von Lichtenberg F; David JR
Eur J Immunol; 2000 Mar; 30(3):834-9. PubMed ID: 10741399
[TBL] [Abstract][Full Text] [Related]
43. Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: T-lymphocyte-mediated immunosuppression.
Nickol AD; Bonventre PF
Infect Immun; 1985 Oct; 50(1):169-74. PubMed ID: 2931377
[TBL] [Abstract][Full Text] [Related]
44. IL-2-stimulated splenocytes reduce infections by Leishmania donovani in vivo.
Olivier M; Eslami Z; Tanner CE
J Parasitol; 1996 Feb; 82(1):78-81. PubMed ID: 8627506
[TBL] [Abstract][Full Text] [Related]
45. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
[TBL] [Abstract][Full Text] [Related]
46. The role of mannose receptor during experimental leishmaniasis.
Akilov OE; Kasuboski RE; Carter CR; McDowell MA
J Leukoc Biol; 2007 May; 81(5):1188-96. PubMed ID: 17261547
[TBL] [Abstract][Full Text] [Related]
47. Suppression of macrophage antimicrobial activity by a tumor cell product.
Szuro-Sudol A; Murray HW; Nathan CF
J Immunol; 1983 Jul; 131(1):384-7. PubMed ID: 6408180
[TBL] [Abstract][Full Text] [Related]
48. Mast cells at the host-pathogen interface: host-protection versus immune evasion in leishmaniasis.
Saha B; Tonkal AM; Croft S; Roy S
Clin Exp Immunol; 2004 Jul; 137(1):19-23. PubMed ID: 15196239
[TBL] [Abstract][Full Text] [Related]
49. Immunoprophylaxis against Kala-Azar. II-Experimental L. donovani infection in Hissar strain albino mice & comparison between mouse adopted and hamster maintained strains.
Jalees S; Jalil S; Pillai CR; Hussain QZ; Topa PK
J Commun Dis; 1982 Jun; 14(2):96-105. PubMed ID: 7153487
[No Abstract] [Full Text] [Related]
50. An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice.
Engwerda CR; Smelt SC; Kaye PM
Exp Parasitol; 1996 Nov; 84(2):195-202. PubMed ID: 8932769
[TBL] [Abstract][Full Text] [Related]
51. Influence of Brugia malayi life stages and BmAFII fraction on experimental Leishmania donovani infection in hamsters.
Murthy PK; Dixit S; Gaur RL; Kumar R; Sahoo MK; Shakya N; Joseph SK; Palne S; Gupta S
Acta Trop; 2008 May; 106(2):81-9. PubMed ID: 18329620
[TBL] [Abstract][Full Text] [Related]
52. Enhancement of infectivity of Leishmania donovani promastigotes by serial mouse passages.
Katakura K; Kobayashi A
J Parasitol; 1985 Jun; 71(3):393-4. PubMed ID: 4009354
[No Abstract] [Full Text] [Related]
53. Suppression of proliferative response and lymphokine production during the progression of a spontaneous tumor.
Varesio L; Giovarelli M; Landolfo S; Forni G
Cancer Res; 1979 Dec; 39(12):4983-8. PubMed ID: 159126
[No Abstract] [Full Text] [Related]
54. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.
Murray HW; Rubin BY; Rothermel CD
J Clin Invest; 1983 Oct; 72(4):1506-10. PubMed ID: 6415111
[TBL] [Abstract][Full Text] [Related]
55. [Leishmaniases: parasitic diseases of the immune system?].
Shuĭkina EE
Med Parazitol (Mosk); 1980; 49(6):16-22. PubMed ID: 7010105
[No Abstract] [Full Text] [Related]
56. Immunotherapy with IL-2-stimulated splenocytes reduces in vitro the level of Leishmania donovani infection in peritoneal macrophages.
Eslami Z; Olivier M; Tanner CE
Int J Parasitol; 1995 Aug; 25(8):975-81. PubMed ID: 8550297
[TBL] [Abstract][Full Text] [Related]
57. Leishmania donovani infection enhances macrophage viability in the absence of exogenous growth factor.
Moore KJ; Turco SJ; Matlashewski G
J Leukoc Biol; 1994 Jan; 55(1):91-8. PubMed ID: 8283144
[TBL] [Abstract][Full Text] [Related]
58. Biotechnology and visceral leishmaniasis in the World Health Organization's Southeast Asian region: research and reality.
Desowitz RS
Southeast Asian J Trop Med Public Health; 1988 Jun; 19(2):163-74. PubMed ID: 3227396
[No Abstract] [Full Text] [Related]
59. Functional activities of the NCTC 1469 macrophage-like cell line: comparison of the NCTC 1469 cell line with various other macrophage-like cell lines.
De Weger RA; Van Loveren H; Van Basten CD; Oskam R; Van Der Zeijst BA; Den Otter W
J Reticuloendothel Soc; 1983 Jan; 33(1):55-66. PubMed ID: 6687612
[No Abstract] [Full Text] [Related]
60. Immunoprophylaxis against kala-azar. IVa. Immunization of golden hamsters and Hissar strain albino mice against Leishmania donovani (an exploratory study).
Jalees S; Jalil S; Topa PK; Hussain QZ
J Commun Dis; 1983 Mar; 15(1):40-7. PubMed ID: 6677687
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
